Husqvarna AB: Interim Report January - September 2014 Oct 22, 2014 02:39AM

STOCKHOLM--(BUSINESS WIRE)-- Regulatory News:

Husqvarna AB (STO:HUSQB):

Kai Wärn, President and CEO:

“Husqvarna Group’s positive trend from the first half year continued into the seasonally smaller third quarter. Total Group sales increased by 3%, adjusted for changes in exchange rates.

Operating income for the third quarter increased by 46% to SEK 301m (206), and the margin rose to 4.4%, driven by improvements across all business areas. On Group level, the favorable development was supported by reduced material costs, higher sales volume and improved productivity. Cash flow was solid, and the net debt/equity ratio improved to 0.50 (0.57).

From a business area perspective, currency adjusted sales for Americas and Construction increased by 6% respectively, while Europe & Asia/Pacific was flat. In terms of earnings, Europe & Asia/Pacific reported higher results and improved margin, Americas’ turn-around showed steady progress reducing the operating loss in the quarter by more than half, and Construction sustained its profitable growth.

As previously communicated, the Group’s current focus is to increase the operating margin from approximately 5% in 2013 to 10% in 2016. On a year-to-date basis, the operating margin has improved by close to 2 percentage points. The positive development has largely been enabled by a successful execution of the Accelerated Improvement Program, which primarily aims to cut product cost by reducing material costs, and improve product mix by focusing on core brands and on products where the Group has leadership positions.

We are now taking the final steps of preparing for next season. Keeping the momentum in the execution of the Accelerated Improvement Program is the priority for 2015. In parallel, the new brand based organization will be fully operational as of January 1, 2015, and forms the base for taking steps towards expansion beyond 2015.

From a short term demand perspective, we expect the fourth quarter to show a stable development compared to the corresponding quarter prior year.”

Third quarter

· Net sales increased to SEK 6,785m (6,349). Adjusted for exchange rate effects, net sales increased 3%.

· Operating income increased 46% to SEK 301m (206). Sales, operating income and margin improved for all business areas.

· Earnings per share increased to SEK 0.31 (0.16).

· Operating cash flow amounted to SEK 1,286 (2,001).

· The net debt/equity ratio improved to 0.50 (0.57).

Telephone conference

A combined press and telephone conference, hosted by Kai Wärn, President and CEO, and Ulf Liljedahl, CFO, will be held at Husqvarna’s office on Regeringsgatan 28 in Stockholm at 10:00 CET on October 22, 2014. To participate by phone, please dial +46 (0) 8 5052 0110 (Sweden) or +44 (0)20 7162 0077 (UK) ten minutes prior to the start of the conference. The conference call will also be audio cast live on www.husqvarnagroup.com/ir (http://www.husqvarna.com/ir). A replay will be available at www.husqvarnagroup.com/ir (http://www.husqvarna.com/ir) later the same day.

Husqvarna Group

Husqvarna Group is the world’s largest producer of outdoor power products including robotic lawn mowers, garden tractors, chainsaws and trimmers. The Group is also the European leader in consumer watering products and one of the world leaders in cutting equipment and diamond tools for the construction and stone industries. The Group’s products and solutions are sold via dealers and retailers to both consumers and professional users in more than 100 countries. Net sales in 2013 amounted to SEK 30 billion, and the Group had 14,000 employees on average in more than 40 countries.

This interim report comprises information which Husqvarna is required to disclose under the Securities Markets Act and/or the Financial Instruments Trading Act. It was released for publication at 08:00 CET on October 22, 2014.

This information was brought to you by Cision http://news.cision.com

Husqvarna AB

Ulf Liljedahl, CFO

+46 8 738 94 42

or

Tobias Norrby

Investor Relations Manager

+46 8 738 93 35

Source: Husqvarna AB


Husqvarna’s CFO to Leave the Group Oct 22, 2014 02:34AM

STOCKHOLM, Sweden--(BUSINESS WIRE)-- Regulatory News:

Husqvarna AB: (STO:HUSQB)

Ulf Liljedahl, CFO of Husqvarna Group since 2011, has decided to leave the Group as of end of February, 2015. Ulf Liljedahl has been appointed President and CEO of Volito Group.

"We would like to thank Ulf for his successful contribution to the Group and wish him all the best in his new position and the future", says Kai Wärn, President and CEO of Husqvarna Group.

The search for a successor has been initiated.

The above information has been made public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 08:00 on October 22, 2014.

Husqvarna Group

Husqvarna Group is the world’s largest producer of outdoor power products including robotic lawn mowers, garden tractors, chainsaws and trimmers. The Group is also the European leader in consumer watering products and one of the world leaders in cutting equipment and diamond tools for the construction and stone industries. The Group’s products and solutions are sold via dealers and retailers to both consumers and professional users in more than 100 countries. Net sales in 2013 amounted to SEK 30 billion, and the Group had 14,000 employees on average in more than 40 countries.

This information was brought to you by Cision http://news.cision.com

Husqvarna AB

+46 8 738 90 80

press@husqvarnagroup.com

Source: Husqvarna AB


NCKU, University of Ottawa Collaboration Leads to Medical Breakthrough in Ovarian Cancer Oct 22, 2014 02:34AM

TAINAN, Taiwan--(BUSINESS WIRE)-- A medical discovery made by a joint research team between National Cheng Kung University (NCKU) in southern Taiwan, and University of Ottawa in Canada will help clinicians to better treat women with ovarian cancer, NCKU revealed.

The team has investigated into why ovarian cancer is often resistant to chemotherapy and identified a protein called gelsolin which plays a critical role in the chemo-resistance.

Conducted by distinguished professor Dr. Dar-Bin Shieh, NCKUH OB/GYN physicians Dr. Cheng-Yang Chou and Dr. Yu-Fang Huang and postdoctoral fellow Pei-Wen Wang, together with Dr. Benjamin Tsang of the University of Ottawa, the research was published in the September issue of the Proceedings of the National Academy of Sciences (PNAS).

According to Dr. Dar-Bin Shieh, though gelsolin was often studied for cellular motility and cytoskeleton re-arrangement in the past, none had thought to link it with cancer drug resistance.

They found that increased levels of gelsolin are associated with aggressive forms of ovarian cancer and are more likely to resist chemotherapy and lead to death.

Dr. Shieh noted that treatments for ovarian cancer are mainly surgical removal and chemotherapy. However, as the cancer developed toward its terminal stages under chemotherapy, it is prone to develop chemo-resistance later with a high probability for recurrence and death.

Both ovarian cancer patients’ sample and culturing cell lines indicate that a higher level of gelsolin expression predicts development of chemo-resistance and a higher chance of recurrence as well as mortality as compared to their counterparts exhibiting a lesser level.

The study concludes the level of gelsolin expression well predict chemo-resistance phenotype of ovarian cancer.

The critical unmet clinical needs in the failure of chemotherapy is derived from the conversion toward chemo-resistance, for which the team has now identified gelsolin to be responsible, Dr. Shieh said.

The short-term goal for future development, Dr. Shieh adds, is to develop a detection method to accurately predict ovarian cancer drug resistance potential, whilst the long-term aim is to develop effective anti-resistance strategy in ovarian cancers.

NCKU news: http://news-en.secr.ncku.edu.tw/bin/home.php

National Cheng Kung University

News Center

Sonia Chuang, +886-6-275-7575 ext. 50042

Fax: +886-6-238-9919

sonia20@mail.ncku.edu.tw

Source: National Cheng Kung University


New Clinical Data Supports Development Of Bertilimumab In Both Ulcerative Colitis And Crohn's Disease Oct 22, 2014 02:30AM

CAMBRIDGE, Mass. and HERZLIYA PITUACH, Israel, Oct. 22, 2014 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ: IMNP; "Immune" or "the Company") announces that Dr. Tomer Adar, a gastro-enterologist at the Institute for Digestive Diseases at Shaare Zedek Medical Center, Israel, is presenting today at the United European Gastro-Enterology week in Vienna, Austria an abstract entitled "The importance of intestinal eotaxin-1 - Eosinophil axis in inflammatory bowel disease, Results of a prospective observational study." The study was supported in part by an unrestricted grant from Immune.

Professor Eran Goldin, Chairman of the Institute for Digestive Diseases at Shaare Zedek Medical Center, part of the Hebrew University School of Medicine in Jerusalem, Israel, commented: "This prospective clinical observational study demonstrates the pivotal role of eotaxin-1 in both Ulcerative Colitis and Crohn's Disease. Ongoing and future clinical trials will assess the relevance of selecting patients based on high eotaxin-1 tissue levels to optimize treatment response with anti-eotaxin 1 drugs such as Bertilimumab."

According to the abstract presented by Professor Goldin's group, this observational clinical study demonstrates elevated tissue Eotaxin-1 levels in both Ulcerative Colitis and Crohn's Disease, especially in more severe, active disease. The increase in tissue but not in serum eotaxin-1 levels suggests its importance as a local mediator of mucosal inflammation. The correlation between tissue eotaxin-1 and tissue eosinophilia in active disease, marks its central role in mediating local inflammation. and also suggests that its role in the pathogenesis of Crohn's Disease is not restricted to eosinophil recruitment.

A previous study, supported in part by a National Institute of Health grant and published on December, 18, 2013 in PlosOne by Professor Keith Wilson at Vanderbilt University Medical Center, highlighted eotaxin-1 as an etiologic factor and therapeutic target in Ulcerative Colitis.

Coburn LA, Horst SN, Chaturvedi R, Brown CT, Allaman MM, et al. (2013) High-Throughput Multi-Analyte Luminex Profiling Implicates Eotaxin-1 in Ulcerative Colitis. PLoS ONE 8(12): e82300. doi:10.1371/journal.pone.0082300

About Ulcerative Colitis

Ulcerative colitis is a chronic, inflammatory immune-related disorder limited to the large bowel (colon and rectum) and only affects the inner lining of the colon. The main symptom is diarrhea that is generally bloody and may be associated with abdominal pain. Loss of appetite and subsequent weight loss are common, as is fatigue. Severe bleeding may result in anemia. Ulcerative colitis can be debilitating and sometimes can lead to life-threatening complications. The symptoms of ulcerative colitis tend to come and go, with fairly long periods in between flare-ups in which patients may experience no distress at all. Major surgery is often involved, and can cure the disease.

About Crohn's Disease

Crohn's disease is an immune-related, chronic inflammatory condition (auto-immune) that can involve any part of the gastrointestinal tract, but most frequently affects the end of the small bowel and the beginning of the large bowel. In Crohn's disease, all layers of the intestine may be involved and there can be normal healthy bowel between patches of diseased bowel. Symptoms include persistent diarrhea, abdominal pain, fever, and occasionally, rectal bleeding. Fatigue, loss of appetite and weight loss also may occur. There is no cure for the disease.

About Immune Pharmaceuticals Inc.

Immune Pharmaceuticals Inc. applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer.  The Company's lead product candidate, bertilimumab, is in clinical development for moderate to severe Ulcerative Colitis as well as Bullous Pemphigoid, an orphan auto-immune dermatological condition. Immune licensed worldwide rights for systemic indications of bertilimumab from iCo Therapeutics (TSX: ICO; OTCQX: ICOTF) in June 2011, while iCo retained rights to all ophthalmic indications. iCo originally licensed the exclusive world-wide rights to bertilimumab in 2006 from MedImmune, the Global Research and Development Arm of AstraZeneca.  Immune's pipeline also includes NanomAbs®, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics, and Amiket™, a Neuropathic Pain drug candidate ready for Phase III. Amiket has received Orphan Drug Designation for Post Herpetic Neuralgia.

For more information, visit Immune's website at www.immunepharmaceuticals.com, the content of which is not a part of this press release.

Erik Penser Bankaktiebolag is engaged as Immune's Certified Adviser on NASDAQ OMX First North Premier.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal" or the negative of those words or other comparable words to be uncertain and forward-looking.  Such forward-looking statements include statements that express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; the risks associated with our ability to continue to meet our obligations under our existing debt agreements; the risk that clinical trials for bertilimumab or AmiKet™ will not be successful; the risk that bertilimumab, AmiKet™ or compounds arising from our NanomAb® program will not receive regulatory approval or achieve significant commercial success; the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet™ on attractive terms, a timely basis or at all; the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later-stage clinical trials; the risk that we will not obtain approval to market any of our product candidates; the risks associated with dependence upon key personnel; the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings which are available at www.sec.gov or at www.immunepharmaceuticals.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-clinical-data-supports-development-of-bertilimumab-in-both-ulcerative-colitis-and-crohns-disease-405025186.html

SOURCE Immune Pharmaceuticals Inc.


Millicom International Cellular: Millicom to drive data takeup with smartapps Oct 22, 2014 02:17AM

- premium apps bundled in monthly packages

- popular apps include Tigo Music, Qello and Gameloft

- new campaign to drive digital lifestyle adoption

STOCKHOLM--(BUSINESS WIRE)-- Millicom (Stockholmsbörsen: MIC), the international telecommunications and media company, announced today the launch of its Tigo “smartapps” service to drive further takeup of data and smartphone usage in Latin America.

The smartapps service: bundling premium services with data

Tigo’s post-paid customers will be able to choose and activate from a group of premium applications included in their monthly data plan:

- Tigo Music: featuring 30 million streamed tracks as well as an online listening facility

- Qello: exclusive full-length HD music documentaries and concerts spanning all genres

- Gameloft: users select four games each month such as Sonic, Assassin’s Creed and Spiderman

- Busuu: with over 200 hours of online lessons to learn eleven different languages, including English, German, French and more.

- Smartbooks: Tigo’s own smartbooks app has a library of 1,000 titles.

With APPtualizate, Tigo’s prepay customers will be able to discover from dozens of apps, which will include locally-relevant content such as maps, cooking, fitness, basic music and film.

The service begins its full rollout in Colombia and will be available in El Salvador and Bolivia later this month and in all Latin American Tigo markets by the end of the first quarter of 2015. With low penetration of debit and credit cards in these countries, the service is a simple way for customers to access mobile content.

Over the past year Millicom has experienced a significant rise in the number of its customers taking data packages with one in four now having mobile online access. Its drivers have included Tigo Music with over 600,000 customers and the FIFA World Cup app which was a top download in five Tigo markets. This has been boosted by the wide availability of smartphones at around $45.

The smartapps campaign: guiding and motivating the consumer

The first phase of the smartapps marketing campaign in Colombia, including a TV spot filmed in Medellin, features the simplicity of using apps on mobile devices as well as the extraordinary range of content available.

It shows the millions of consumers who may be unfamiliar with the concept of apps, how they work and how useful and entertaining they can be to position Tigo as a trusted and friendly provider.

The campaign reinforces the Tigo Smart brand which promotes a selection of smartphone products and services designed to make customers’ lives easier and the smartphone experience more fun.

Commenting on the launch of the new service today, Millicom’s CEO and President Hans-Holger Albrecht said “Online use on the go keeps on growing and now our smartapps service will reinforce this decisive shift from voice to data use on mobile devices. It’s a key part of our strategy to provide a digital lifestyle and promote stronger customer loyalty with valued services and attractive bundles.”

About Millicom

Millicom (STO: MIC) is a leading international telecommunications and media company dedicated to emerging markets in Latin America and Africa. Millicom sets the pace when it comes to providing digital lifestyle services to the world’s emerging markets, giving access to the world, primarily through mobile devices. Operating in fourteen countries, primarily using the Tigo brand, Millicom offers innovative and customer-centric products. Millicom employs more than 16,000 people and provides mobile, cable, broadband, TV content, online and financial services to over 50 million customers. Founded in 1990, Millicom is headquartered in Luxembourg and listed on NASDAQ OMX Stockholm under the symbol MIC. In 2013 Millicom generated revenue of $5.16 billion and EBITDA of $1.9 billion.

This information was brought to you by Cision http://news.cision.com

Millicom International Cellular

For more please visit: www.millicom.com or contact:

Press Enquiries:

Julian Eccles, VP, Corporate Communications

+44 7720 409374

press@millicom.com

or

Investor Enquiries:

Nicolas Didio, Director of Investor Relations

+44 203 249 2220

investors@millicom.com

Source: Millicom International Cellular


More Press Releases

View Older Stories

Oct 22, 2014 02:15AM Nidec Announces Financial Results for Fiscal Second Quarter and Six Months Ended September 30, 2014
Oct 22, 2014 02:15AM Nidec Announces Financial Results for Fiscal Second Quarter and Six Months Ended September 30, 2014
Oct 22, 2014 02:13AM Millicom International Cellular: Transformation and growth as UNE makes a strong start
Oct 22, 2014 02:05AM Bavarian Nordic Enters Licensing and Supply Agreement with Janssen on MVA-BN(R) Ebola Vaccine
Oct 22, 2014 02:05AM APS Upset Training President Joins NBAA Safety Committee
Oct 22, 2014 02:02AM Johnson & Johnson Announces Major Commitment to Speed Ebola Vaccine Development and Significantly Expand Production
Oct 22, 2014 02:01AM BARC's The BI Survey 14: "Cloud Business Intelligence is clearly a space Yellowfin dominates"
Oct 22, 2014 02:01AM JASON RUEDY: The Home Loan Arranger, Urges Potential Buyers to Investigate Vacation Home Buying Opportunities
Oct 22, 2014 02:01AM Asplundh Adds Propane Autogas Trucks to its Fleet
Oct 22, 2014 02:00AM Tricks, Treats, Ghosts, Goblins Abound in New Halloween Story
Oct 22, 2014 02:00AM How the Entitlement Mentality is Hurting Marriages, Explains Relationship Expert Hellen Chen
Oct 22, 2014 02:00AM Avid Collector Seeks Vintage Jimi Hendrix 1969 Sportpalast Berlin Germany Concert Poster
Oct 22, 2014 02:00AM Memoir reveals Hollywood's lights, shadows in poetry
Oct 22, 2014 02:00AM DSP Group Delivers HD Voice and Home Automation Utilizing Qualcomm Internet Processor
Oct 22, 2014 02:00AM Key Properties at Runway Playa Vista Choose Allura for Protection
Oct 22, 2014 02:00AM DSP Group Delivers HD Voice and Home Automation Utilizing Qualcomm Internet Processor
Oct 22, 2014 02:00AM GW Pharmaceuticals Announces Epidiolex(R) Receives Orphan Designation From European Medicines Agency for the Treatment of Dravet Syndrome
Oct 22, 2014 02:00AM Eurotunnel Group: Activity in the Third Quarter of 2014
Oct 22, 2014 02:00AM B/E Aerospace Reports Third Quarter 2014 Financial Results
Oct 22, 2014 02:00AM Lewis Roca Rothgerber Welcomes Four New Associates in Phoenix
Oct 22, 2014 02:00AM Women Hold Greater Proportion of CEO and Board Seats at Non-Profits Than at For-Profit Companies in the Philadelphia Region
Oct 22, 2014 02:00AM BGC Partners Commences Cash Tender Offer To Acquire GFI Group For $5.25 Per Share
Oct 22, 2014 01:59AM Yingli Green Energy Hosts Fifth Annual Global Investor Day in Las Vegas, USA
Oct 22, 2014 01:55AM NoHo Urgent Care Offers Exclusive $85 Medical Exams for Patients
Oct 22, 2014 01:37AM DBV Technologies S.A. Announces Pricing of Global Offering
Oct 22, 2014 01:37AM DBV Technologies S.A. Announces Pricing of Global Offering
Oct 22, 2014 01:35AM Author Reveals Thoughts through Book of Personal Commentaries
Oct 22, 2014 01:20AM TECHNICOLOR : Third quarter 2014 Revenues
Oct 22, 2014 01:15AM New Biography Shows Exciting Life of Lone Ranger's Radio Show Actor
Oct 22, 2014 01:15AM Wholesale Stainless Steel Exit Buttons Provided by Chinese Magnetic Lock Supplier Locks-Magnetic.com
Oct 22, 2014 01:15AM ASETEK – Q3 2014 Progress in Both Segments
Oct 22, 2014 01:14AM The Best Cheap WordPress Hosting Companies In 2014 Revealed –Top10BestSEOHosting.com
Oct 22, 2014 01:05AM Daniel Pink, NYT Bestselling Author, Partners with RiseSmart to Host "Think Like A Leader: Drive Your HR Career" Webinar
Oct 22, 2014 01:03AM Norsk Hydro : Third quarter 2014: Lower Alunorte costs and higher all-in metal price lift results
Oct 22, 2014 01:02AM Recycled Aluminium Innovation Supports Circular Economy
Oct 22, 2014 01:02AM Young Teens Are Crowned UK's Best Young Drivers - Before Legal Driving Age
Oct 22, 2014 01:02AM M. Scott Robertson's Crime Thriller Receives New Marketing Push
Oct 22, 2014 01:01AM CCW Global Deploys Cyber Insurance Facilities to Assist With Digital Risk Cover
Oct 22, 2014 01:01AM The Culinary School at Eva's Village Provides Job Training But More Importantly Assists Students in Finding Positions in the Food Service Industry
Oct 22, 2014 01:01AM eMazzanti Offers Hands-on Microsoft Office 365 Experience to NYC Area Businesses
Oct 22, 2014 01:01AM Advisory - Thurs. Oct.23, 1:00 PM at Curtis Hixon Park: Two Henrys Brewing Company Honors Florida Railroad Barons Henry Plant and Henry Flagler
Oct 22, 2014 01:00AM Douglas County Schools Hyundai Raffle Raises Over $45,000
Oct 22, 2014 01:01AM Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate
Oct 22, 2014 01:00AM Ocean Reef Vacation Rentals & Real Estate Is Official Sponsor of 2014 30A 10K Race
Oct 22, 2014 01:00AM Local Schools Can Earn Funds With Gold'n Plump® Purchases
Oct 22, 2014 01:00AM Mina Group CFO Named 'Revolutionary CFO of the Year' - 7th Annual MENA CFO Awards
Oct 22, 2014 01:00AM Switzerland is the Best Place for Expat Life
Oct 22, 2014 01:00AM Dalma Capital Management and Emirates Foundation Sign Donation Agreement
Oct 22, 2014 01:00AM Nova Medical to Open New Occupational Medicine Center in Arlington, Texas
Oct 22, 2014 01:00AM AssetOptics Announces the Release of AssetOptics 2.6
View Older Stories